BIAL, a hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study.
Go back
Investment
BIAL Announces a Novel Therapy for GBA1 Parkinson's Disease
The Portuguese company BIAL is focused on neurosciences and rare diseases.
finanznachrichten/AICEP
07th Jan 2025
